BI increases commitments to sustainable development BI increases commitments to sustainable development At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development
Research ruminant animal health well-being Research ruminant animal health well-being Boehringer Ingelheim supports young scientists and veterinarians dedicated to ruminant health research
Boehringer-Ingelheim's-half-year-figures-2021 Boehringer-Ingelheim's-half-year-figures-2021 Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.
commitments to sustainable development commitments to sustainable development On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities
Research-collaboration-Gubra-obesity-treatment Research-collaboration-Gubra-obesity-treatment Boehringer Ingelheim and Gubra enter collaboration to identify and validate targets and innovative peptides for the treatment of obesity.
Boehringer Ingelheim partners with PetMedix Boehringer Ingelheim partners with PetMedix Partnering with PetMedix on Ky9™ platform cutting edge technology as a means to bring innovative new therapies to improve health of animals
collaboration-kings-college-london collaboration-kings-college-london Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia
university-of-medical-excellence-harvard university-of-medical-excellence-harvard A program designed by Harvard Medical School Executive Education with the goal of accelerating clinical development and medical affairs
License deal with A*STAR to develop cancer antibodies License deal with A*STAR to develop cancer antibodies License deal with A*STAR to develop cancer antibodies
PRRS vaccine celebrates 25 years in Europe PRRS vaccine celebrates 25 years in Europe Boehringer Ingelheim celebrates 25 years to combat PRRS in Europe
environmental sustainability commitments environmental sustainability commitments On the occasion of the 2021 UN Climate Change Conference (COP26), Boehringer Ingelheim shares an update on its strategic approach to sustainability
Clinical-phase2-trials-NASH-and-obesity Clinical-phase2-trials-NASH-and-obesity Boehringer Ingelheim and Zealand Pharma announced Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 for adults living with obesity or NASH.
Partnership Boehringer Ingelheim Lifebit health data Partnership Boehringer Ingelheim Lifebit health data Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
GastroGard the first imported equine drug in China GastroGard the first imported equine drug in China GastroGard® approved as the first imported equine drug in China. Boehringer Ingelheim officially starts equine health business in China.
ArisGlobal acquires Boehringer Ingelheim technology ArisGlobal acquires Boehringer Ingelheim technology Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
PatientView survey PatientView survey Boehringer Ingelheim among top ten most “patient-centric” pharma companies
cystic fibrosis phase II trial cystic fibrosis phase II trial The first patient has been enrolled in a phase II trial to evaluate an innovative treatment for cystic fibrosis, inhaled via the Respimat® inhaler
FRONTLINE® becomes Brand of the Year 2021-22 FRONTLINE® becomes Brand of the Year 2021-22 FRONTLINE® becomes Brand of the Year 2021-2022 in World Branding Awards
Boehringer Ingelheim announces collaboration with MabGenesis Boehringer Ingelheim announces collaboration with MabGenesis Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine
biopharmaceuticals-in-china biopharmaceuticals-in-china Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.
Mastitis dairy cows prevent antibiotic resistance Mastitis dairy cows prevent antibiotic resistance The Clinical and Laboratory Standards Institute (CLSI) approved revised interpretive criteria for the susceptibility testing of a mastitis product.
Making-more-health-together-2021 Making-more-health-together-2021 1,200 participants from around the world join virtual convention on November 11-12
TwistPak Mixing platform for swine vaccines TwistPak Mixing platform for swine vaccines TwistPak® allows for fresh mixing of Ingelvac CircoFLEX® and Ingelvac MycoFLEX® on farm in less than 5 seconds
Reduction of Salmonella in swine after vaccination Reduction of Salmonella in swine after vaccination Authorities acknowledge reduction of Salmonella after vaccination with Enterisol® Ileitis